 |
 |
|
 |
| uρtuΐ Υ°β`w€ΊvΜ€ΖΡΜf[^Ε·B |
|
[ _@Ά ]
| 1. |
Sakuraba H., Togawa T., Tsukimura T., Kato H.: Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin. Exp. Nephrol., 22: 843-849, 2018. doi: 10.1007/s10157-017-1525-3.
|
| 2. |
Ogawa Y., Irisa M., Sano T., Yanagi Y., Furusawa E., Saito T., Yamanaka S., Itoh K., Sakuraba H., Oishi K.: Improvement in dysmyelination by the inhibition of microglial activation in a mouse model of Sandhoff disease. NeuroReport, 29: 962-967, 2018. doi: 10.1097/WNR.0000000000001060.
|
| 3. |
Tomanin R., Karageorgos L., Zanetti A., Al-Sayed M., Bailey M., Miller N., Sakuraba H., Hopwood J.J.: Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene. Hum Mutat., 39: 1788-1802, 2018. doi: 10.1002/humu.23613.
|
| 4. |
Ogawa Y., Furusawa E., Saitoh T., Sugimoto H., Omori T., Shimizu S., Kondo H., Yamazaki M., Sakuraba H., Oishi K.: Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of Sandhoff disease. Neurobiol. Dis., 118: 142-154, 2018. doi: 10.1016/j.nbd.2018.07.014.
|
| 5. |
Sakuraba H., Tsukimura T., Togawa T., Tanaka T., Ohtsuka T., Sato A., Shiga T., Saito S., Ohno K.: Fabry disease in a Japanese population|molecular and biochemical characteristics. Mol. Genet. Metab. Reports, 17: 73-79, 2018. doi.org/10.1016/j.ymgmr.2018.10.004.
|
|
|
 |
|
|
|
|
|
|
|
|
